Literature DB >> 25956681

Budesonide inhalation ameliorates endotoxin-induced lung injury in rabbits.

Wei Gao1, Nanying Ju2.   

Abstract

Acute respiratory distress syndrome (ARDS) is a serious clinical problem that has a 30-50% mortality rate. Budesonide has been used to reduce lung injury. This study aims to investigate the effects of nebulized budesonide on endotoxin-induced ARDS in a rabbit model. Twenty-four rabbits were randomized into three groups. Rabbits in the control and budesonide groups were injected with endotoxin. Thereafter, budesonide or saline was instilled, ventilated for four hours, and recovered spontaneous respiratory. Peak pressure, compliance, and PaO2/FiO2 were monitored for 4 h. After seven days, PaO2/FiO2 ratios were measured. Wet-to-dry weight ratios, total protein, neutrophil elastase, white blood cells, and percentage of neutrophils in BALF were evaluated. TNF-α, IL-1β, IL-8, and IL-10 in BALF were detected. Lung histopathologic injury and seven-day survival rate of the three groups were recorded. Peak pressure was downregulated, but compliance and PaO2/FiO2 were upregulated by budesonide. PaO2/FiO2 ratios significantly increased due to budesonide. Wet-to-dry weight ratios, total protein, neutrophil elastase, white blood cells and percentage of neutrophils in BALF decreased in the budesonide group. TNF-α, IL-1β, and IL-8 levels decreased in BALF, while IL-10 levels increased in the budesonide group. Lung injuries were reduced and survival rate was upregulated by budesonide. Budesonide effectively ameliorated respiratory function, attenuated endotoxin-induced lung injury, and improved the seven-day survival rate.
© 2015 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Budesonide; endotoxin; lung injury

Mesh:

Substances:

Year:  2015        PMID: 25956681      PMCID: PMC4935336          DOI: 10.1177/1535370215584938

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  36 in total

Review 1.  The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling.

Authors:  M Karin; M Delhase
Journal:  Semin Immunol       Date:  2000-02       Impact factor: 11.130

Review 2.  Cytokine-mediated inflammation in acute lung injury.

Authors:  Richard B Goodman; Jérôme Pugin; Janet S Lee; Michael A Matthay
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

Review 3.  Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group.

Authors:  Michael A Matthay; Guy A Zimmerman; Charles Esmon; Jahar Bhattacharya; Barry Coller; Claire M Doerschuk; Joanna Floros; Michael A Gimbrone; Eric Hoffman; Rolf D Hubmayr; Mark Leppert; Sadis Matalon; Robert Munford; Polly Parsons; Arthur S Slutsky; Kevin J Tracey; Peter Ward; Dorothy B Gail; Andrea L Harabin
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

4.  Single high-dose dexamethasone and sodium salicylate failed to attenuate phosgene-induced acute lung injury in rats.

Authors:  Fangfang Liu; Jürgen Pauluhn; Hubert Trübel; Chen Wang
Journal:  Toxicology       Date:  2013-11-23       Impact factor: 4.221

5.  Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury.

Authors:  Patricia R M Rocco; Alba B Souza; Debora S Faffe; Caroline P Pássaro; Flávia B Santos; Elnara M Negri; Januário G M Lima; Renata S Contador; Vera L Capelozzi; Walter A Zin
Journal:  Am J Respir Crit Care Med       Date:  2003-07-03       Impact factor: 21.405

6.  Protection from lipopolysaccharide-induced lung injury by augmentation of airway S-nitrosothiols.

Authors:  Harvey E Marshall; Erin N Potts; Zachary T Kelleher; Jonathan S Stamler; W Michael Foster; Richard L Auten
Journal:  Am J Respir Crit Care Med       Date:  2009-03-26       Impact factor: 21.405

7.  Clinical risks for development of the acute respiratory distress syndrome.

Authors:  L D Hudson; J A Milberg; D Anardi; R J Maunder
Journal:  Am J Respir Crit Care Med       Date:  1995-02       Impact factor: 21.405

8.  Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors.

Authors:  R I Scheinman; A Gualberto; C M Jewell; J A Cidlowski; A S Baldwin
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

9.  Neutrophil elastase and systemic inflammatory response syndrome in the initiation and development of acute lung injury among critically ill patients.

Authors:  Seitaro Fujishima; Hiroshi Morisaki; Akitoshi Ishizaka; Yoshifumi Kotake; Masaru Miyaki; Kikuo Yoh; Kazuhiko Sekine; Junichi Sasaki; Sadatomo Tasaka; Naoki Hasegawa; Yohko Kawai; Junzo Takeda; Naoki Aikawa
Journal:  Biomed Pharmacother       Date:  2007-07-31       Impact factor: 6.529

10.  Therapeutic effect of inhaled budesonide (Pulmicort® Turbuhaler) on the inflammatory response to one-lung ventilation.

Authors:  N Y Ju; H Gao; W Huang; F F Niu; W X Lan; F Li; W Gao
Journal:  Anaesthesia       Date:  2013-10-28       Impact factor: 6.955

View more
  4 in total

1.  Use of aerosol inhalation treatment with budesonide and terbutaline sulfate on acute pediatric asthmatic bronchitis.

Authors:  Fangfang Bian; Yue-E Wu; Chong-Lin Zhang
Journal:  Exp Ther Med       Date:  2017-06-26       Impact factor: 2.447

2.  Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice.

Authors:  Liang Dong; Yu-Hang Zhu; De-Xing Liu; Juan Li; Peng-Cheng Zhao; Yuan-Ping Zhong; Yong-Qin Chen; Wei Xu; Zhao-Qiong Zhu
Journal:  J Immunol Res       Date:  2019-02-27       Impact factor: 4.818

Review 3.  Corticosteroids in Acute Lung Injury: The Dilemma Continues.

Authors:  Daniela Mokra; Pavol Mikolka; Petra Kosutova; Juraj Mokry
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

4.  Budesonide ameliorates lung injury induced by large volume ventilation.

Authors:  Ying-Nan Ju; Kai-Jiang Yu; Guo-Nian Wang
Journal:  BMC Pulm Med       Date:  2016-06-04       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.